Us Bancorp \De\ Inozyme Pharma, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 44 shares of INZY stock, worth $128. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$128

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Oct 28, 2024	BUY	$4.31 - $6.0 $189 - $264	44 New	44 $0
Q3 2023 Nov 03, 2023	BUY	$4.09 - $7.0 $527 - $903	129 New	129 $0

Others Institutions Holding INZY

# of Institutions

Shares Held

53M

Call Options Held

3.7K

Put Options Held

5.8K

Adage Capital Partners Gp, L.L.C. Boston, MA

5.67M
Shares

$16.6 Million
0.05% of portfolio
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA

4.49M
Shares

$13.2 Million
18.53% of portfolio
Sofinnova Investments, Inc. Menlo Park, CA

4.28M
Shares

$12.5 Million
2.12% of portfolio
Eventide Asset Management, LLC Boston, MA

4.13M
Shares

$12.1 Million
0.38% of portfolio
Rock Springs Capital Management LP Baltimore, MD

3.8M
Shares

$11.1 Million
0.68% of portfolio

View Full List

About Inozyme Pharma, Inc.

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $118M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

More about INZY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account